Healio

FDA approves Eylea HD for macular edema after retinal vein occlusion

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
Ophthalmology Times

Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
TipRanks on MSN

Regeneron announces FDA approval for Eylea HD Injection 8 mg for macular edema

Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal ...
Managed Healthcare Executive

FDA approves Eylea HD for retinal vein occlusion

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
Ophthalmology Advisor

In Diabetic Macular Edema, Patient Age May Affect Anti-VEGF Response

Older age in adults with diabetic macular edema (DME) appears to be associated with less robust visual and anatomic gains from anti-vascular endothelial growth factor (VEGF) therapy, according to ...